Exhibiting at VIV Asia 2025

NAM Group of Industries Private Limited, based in Mumbai, India, is a diversified pharmaceutical and chemical manufacturing enterprise specializing in Active Pharmaceutical Ingredients (APIs), intermediates, and phase transfer catalysts for both human and veterinary applications. With over a decade of operations, NAM Group has established itself as a reliable partner in the global pharmaceutical supply chain, catering to clients across Asia, Africa, Europe, and Latin America.

The company operates with a mission to deliver high-quality, cost-effective ingredients while adhering to global standards of safety, sustainability, and regulatory compliance.

Core Business and Product Portfolio

NAM Group’s core business revolves around the manufacturing of APIs and chemical intermediates used in the production of essential medicines. Their expansive product portfolio includes:

• Human APIs

  • Paracetamol: Widely used analgesic and antipyretic
  • Ibuprofen: Non-steroidal anti-inflammatory drug (NSAID)
  • Metformin: First-line medication for the treatment of type 2 diabetes

• Veterinary APIs

  • Amoxicillin: Broad-spectrum antibiotic
  • Tylosin: Used in livestock feed for disease prevention and treatment
  • Enrofloxacin: Fluoroquinolone antibiotic for veterinary medicine

• Pharmaceutical Intermediates

  • 4-Aminophenol: Key intermediate in paracetamol production
  • 2-Acetylfuran: Used in fine chemical synthesis

• Phase Transfer Catalysts

  • Tetrabutylammonium Bromide (TBAB)
  • Benzyltriethylammonium Chloride (BTEAC)

All products are offered in compliance with international pharmacopeia standards including USP, EP, and BP, as required by clients.

Unique Selling Proposition

NAM Group’s major strengths lie in its vertically integrated production, regulatory compliance, and its ability to provide consistent quality at competitive pricing. Key differentiators include:

• GMP-certified manufacturing units
• Dedicated R&D and quality assurance teams
• Ability to handle large volume orders with flexible production capacities
• Custom synthesis and contract manufacturing capabilities

The company’s operational agility allows it to rapidly meet customer demands across both generic and specialty drug manufacturing sectors.

Financials and Global Trade Insights

While privately held and not required to disclose detailed financials, NAM Group has demonstrated steady growth through its export activities and strategic partnerships.

• Annual Revenue Estimate: USD 15–20 million (as per industry sources)
• Export Presence: Over 30 countries including Nigeria, Egypt, Bangladesh, Indonesia, Brazil, and Mexico
• Global Shipment Footprint (2020–2024):
  • Estimated 2,000+ international shipments
  • Average shipment size ranges from 500 kg to 20 MT
  • Primary export commodities: Paracetamol, Ibuprofen, Tylosin

(Source: Industry trade platforms and customs shipment records)

Target Market

NAM Group primarily serves:

• Generic drug manufacturers
• Veterinary pharmaceutical producers
• Feed supplement companies
• Bulk drug traders and distributors
• Chemical processing industries requiring specialty intermediates

The company’s product line is tailored for both human and animal health sectors, offering dual-segment capabilities under one brand umbrella.

Capabilities

• Multiple production lines for simultaneous API manufacturing
• Dedicated clean rooms and controlled environments
• In-house analytical lab equipped with HPLC, GC, UV Spectrophotometers
• Regulatory documentation support including DMF, COA, MOA, and stability data
• Experienced logistics team for export handling and customs compliance

Certifications and Compliance

• WHO-GMP Certified
• ISO 9001:2015 Quality Management System
• ISO 14001 Environmental Compliance
• Compliance with REACH (where applicable)
• Drug License issued by Government of India for both API and intermediate production

Customer Testimonials

“NAM Group has been a dependable source of quality APIs for our generics manufacturing operations. Their delivery and documentation have been consistent.”
– Procurement Head, Pharma Company (Egypt)

“We chose NAM for their veterinary APIs. The quality of Tylosin and Enrofloxacin meets all our test parameters, and their customer support is excellent.”
– QA Director, Veterinary Formulations (Vietnam)

Major Achievements

• Approved supplier to several WHO prequalified medicine manufacturers
• Expanded manufacturing footprint with new intermediate facility commissioned in 2022
• Recognized as a top emerging exporter by Pharmexcil India
• Launched integrated CRM system to enhance customer order tracking and technical support

With a steadfast focus on quality, compliance, and innovation, NAM Group of Industries continues to strengthen its global presence as a trusted manufacturer of life-saving pharmaceutical and veterinary ingredients.